AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Caribou Biosciences Inc (NASDAQ:CRBU)
1.275 USD
+0.185 16.973%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.09 |
|---|---|
| Change | +0.185 16.973% |
| 52 W H/L (in USD) | 8.590/2.940 |
| EBITDA (in USD) | -127.299M |
| PE Ratio | -- |
| Volume | 1412061 |
| Diluted Eps TTM | -1.39 |
| Total Assets (in USD) | 440.968M |
|---|---|
| Total Liabilities (in USD) | 72.567M |
| Revenue TTM (in USD) | 33.404M |
| Cash (in USD) | 51.162M |
| Market Cap (in USD) | 270.050 M |
| Revenue Per Share TTM | 0.413 |
| Gross Profit TTM (in USD) | -68.379M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Caribou Biosciences Inc
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Employees: 158
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Steven B. Kanner | Chief Scientific Officer | 1959 |
| 2. | Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, Pres & Director | 1986 |
| 3. | Mr. Jason V. O'Byrne M.B.A. | Chief Financial Officer | 1969 |
| 4. | Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corp. Sec. | 1955 |
| 5. | Mr. Daniel Poon | VP of Operations & Information Technology | NA |
| 6. | Dr. Justin Skoble | VP of Technical Operations | NA |
| 7. | Ms. Amy Figueroa C.F.A. | VP of Investor Relations & Corp. Communications | NA |
| 8. | Ms. Cindy Hayashi | VP of HR | NA |
| 9. | Ms. Ruhi A. Khan M.B.A. | Chief Bus. Officer | 1975 |
| 10. | Dr. Syed Ali-aamir Rizvi M.D. | Chief Medical Officer | 1967 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+1.930 2.657% | 74.15 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.352 0.482% | 72.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+4.320 0.973% | 443.83 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+12.300 2.546% | 485.54 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Income Before Tax | -99.351M | -66.602M | -36.127M | -30.968M |
| Minority Interest | - | - | - | - |
| Net Income | -99.421M | -66.923M | -34.308M | -23.431M |
| Selling General Administrative | 38.02M | 24.322M | 14.06M | 16.458M |
| Gross Profit | 13.851M | 9.598M | 12.361M | 5.788M |
| Reconciled Depreciation | 1.622M | 0.984M | 0.9M | 0.751M |
| Ebit | -106.399M | -66.979M | -36.124M | -34.305M |
| Ebitda | -106.266M | -68.178M | -34.474M | -32.507M |
| Depreciation And Amortization | 0.133M | -1.199M | 1.65M | 1.798M |
| Operating Income | -106.399M | -66.979M | -36.124M | -34.305M |
| Other Operating Expenses | 120.25M | 76.577M | 48.485M | 40.093M |
| Interest Expense | 8.537M | 0.008M | 0.02M | 0.004M |
| Tax Provision | 0.07M | 0.321M | -1.819M | -7.537M |
| Interest Income | - | 0.148M | 0.236M | 1.047M |
| Net Interest Income | - | 0.14M | 0.216M | 1.043M |
| Income Tax Expense | 0.07M | 0.321M | -1.819M | -7.537M |
| Total Revenue | 13.851M | 9.598M | 12.361M | 5.788M |
| Total Operating Expenses | 120.25M | 76.577M | 48.485M | 40.093M |
| Cost Of Revenue | - | - | - | - |
| Total Other Income Expense Net | 7.048M | 0.377M | -0.003M | 3.337M |
| Net Income From Continuing Ops | -99.421M | -66.923M | -34.308M | -23.431M |
| Net Income Applicable To Common Shares | -99.421M | -66.923M | -34.308M | -23.431M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 440.968M | 373.765M | 442.356M | 36.046M | 61.933M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 6.155M | 1.119M | 0.671M | 0.76M | 0.373M |
| Total Liab | 72.567M | 72.894M | 54.531M | 59.483M | 54.47M |
| Total Stockholder Equity | 368.401M | 300.871M | 387.825M | -23.437M | 7.463M |
| Other Current Liab | 20.758M | 16.079M | 0.788M | 8.973M | 6.292M |
| Common Stock | 0.008M | 0.006M | 0.006M | 0.001M | 0.001M |
| Capital Stock | 0.008M | 0.006M | 0.006M | 0.001M | 0.001M |
| Retained Earnings | -299.285M | -197.215M | -97.794M | -30.871M | 3.437M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 1.538M | 0.975M | 0.612M | 0.593M |
| Cash | 51.162M | 58.338M | 240.42M | 15.953M | 41.07M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 28.302M | 28.128M | 25.829M | 12.389M | 10.078M |
| Current Deferred Revenue | 2.847M | 9.937M | 8.703M | 0.161M | 0.717M |
| Net Debt | -23.677M | -30.592M | -240.42M | -14.375M | -40.538M |
| Short Term Debt | 1.577M | 0.966M | 12.348M | 0.654M | 0.532M |
| Short Long Term Debt | - | - | - | 0.847M | 0.532M |
| Short Long Term Debt Total | 27.485M | 27.746M | - | 1.578M | 0.532M |
| Other Stockholder Equity | 667.648M | 499.598M | 43.392M | -33.89M | -37.298M |
| Property Plant Equipment | - | 10.678M | 4.887M | 3.502M | 4.332M |
| Total Current Assets | 338.841M | 260.248M | 391.192M | 24.306M | 57.008M |
| Long Term Investments | 51.33M | 77.071M | 45.302M | 7.626M | 0M |
| Short Term Investments | 277.665M | 189.325M | 135.412M | 0M | 8.401M |
| Net Receivables | 3.859M | 4.664M | 8.124M | 5.16M | 3.982M |
| Long Term Debt | - | - | - | 0.924M | - |
| Inventory | - | -62.571M | -31.111M | 2.433M | 3.182M |
| Accounts Payable | 3.12M | 1.146M | 3.99M | 2.601M | 2.537M |
| Accumulated Other Comprehensive Income | 0.03M | -1.518M | -0.135M | -3.096M | -2.258M |
| Non Currrent Assets Other | 1.586M | 1.538M | 0.975M | 0.612M | 0.593M |
| Non Current Assets Total | 102.127M | 113.517M | 51.164M | 11.74M | 4.925M |
| Capital Lease Obligations | 27.108M | 27.746M | - | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|
| Investments | -86.195M | -173.276M | 7.668M | 28.117M |
| Total Cashflows From Investing Activities | -93.249M | -176.397M | 6.363M | 27.233M |
| Total Cash From Financing Activities | 2.133M | 433.429M | 1.735M | 0.172M |
| Net Income | -99.421M | -66.923M | -34.308M | -23.431M |
| Change In Cash | -182.082M | 224.513M | -25.117M | -4.601M |
| Begin Period Cash Flow | 240.466M | 15.953M | 41.07M | 45.671M |
| End Period Cash Flow | 58.384M | 240.466M | 15.953M | 41.07M |
| Total Cash From Operating Activities | -90.966M | -32.519M | -33.215M | -32.006M |
| Depreciation | 1.622M | 0.984M | 0.9M | 0.751M |
| Other Cashflows From Investing Activities | -0.6M | -1M | - | - |
| Dividends Paid | - | - | - | - |
| Change To Inventory | - | -2.2M | 1.355M | -2.224M |
| Sale Purchase Of Stock | - | 432.398M | - | - |
| Other Cashflows From Financing Activities | -93.249M | 112.528M | 1.848M | 0.217M |
| Capital Expenditures | 7.054M | 3.121M | 1.315M | 0.884M |
| Change In Working Capital | -4.204M | 29.067M | 0.177M | -8.267M |
| Other Non Cash Items | -0.584M | 2.426M | -1.789M | -2.293M |
| Free Cash Flow | -98.02M | -35.64M | -34.53M | -32.89M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | SPDR® S&P Biotech ETF | 1 year ago | 4203889 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 1 year ago | 2768629 |
| 3. | iShares Russell 2000 ETF | 1 year ago | 1908273 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 1222859 |
| 5. | Belfius Equities Cure C Cap | 1 year ago | 1145000 |
| 6. | Candriam Global Equities Oncology | 1 year ago | 1145000 |
| 7. | Fidelity Small Cap Index | 1 year ago | 837957 |
| 8. | iShares Russell 2000 Value ETF | 1 year ago | 758393 |
| 9. | Selectra J. Lamarck Biotech A | 1 year ago | 757300 |
| 10. | iShares Biotechnology ETF | 1 year ago | 583163 |
| 11. | State St Russell Sm/Mid Cp® Indx NL Cl C | 1 year ago | 504192 |
| 12. | Fidelity Extended Market Index | 1 year ago | 476702 |
| 13. | JPM Thematics Genetic Thrps C2 Acc USD | 1 year ago | 462735 |
| 14. | Direxion Daily S&P Biotech Bull 3X ETF | 1 year ago | 423044 |
| 15. | Schwab US Small-Cap ETF™ | 1 year ago | 389055 |
| 16. | DFA US Micro Cap I | 1 year ago | 376947 |
| 17. | DFA US Small Cap I | 1 year ago | 332731 |
| 18. | Dimensional US Targeted Value ETF | 1 year ago | 325393 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 1 year ago | 311580 |
| 20. | Vanguard Russell 2000 ETF | 1 year ago | 305450 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | BlackRock Inc | 1 year ago | 7068468 |
| 2. | Partner Fund Management LP | 1 year ago | 6483270 |
| 3. | Avidity Partners Management LP | 1 year ago | 5785352 |
| 4. | State Street Corporation | 1 year ago | 5119666 |
| 5. | Vanguard Group Inc | 1 year ago | 4110795 |
| 6. | Alkeon Capital Management, LLC | 1 year ago | 3113564 |
| 7. | Paradigm Biocapital Advisors LP | 1 year ago | 2923851 |
| 8. | Elmwood Wealth Management, Inc. | 1 year ago | 2364260 |
| 9. | Dimensional Fund Advisors, Inc. | 1 year ago | 2087121 |
| 10. | Geode Capital Management, LLC | 1 year ago | 1794648 |
| 11. | Bank of America Corp | 1 year ago | 1593136 |
| 12. | FMR Inc | 1 year ago | 1444576 |
| 13. | Goldman Sachs Group Inc | 1 year ago | 1320080 |
| 14. | Candriam Luxembourg S.C.A. | 1 year ago | 1145063 |
| 15. | Woodline Partners LP | 1 year ago | 1140671 |
| 16. | Morgan Stanley - Brokerage Accounts | 1 year ago | 1104813 |
| 17. | Kynam Capital Management, LP | 1 year ago | 1068527 |
| 18. | Pictet Asset Manangement SA | 1 year ago | 940911 |
| 19. | SILVERARC CAPITAL MANAGEMENT, LLC | 1 year ago | 900818 |
| 20. | Fidelity International Ltd | 1 year ago | 860666 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...